T14
vs
JNJ
T14
JNJ
Over the past 12 months, T14 has outperformed JNJ, delivering a return of +47% compared to the JNJ's +46% growth.
This Feature is Available on
Paid Plans
Paid Plans
This Feature is Available on Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
14-day money-back guarantee
Smart Verdict
AI-Powered
Not Sure Which Stock Wins?
Let AI Decide.
Let AI Decide.
T14
JNJ
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Summarizing...
We need a little more time to summarize the results
Valuation Comparison
T14
Intrinsic Value
2.22
USD
Overvaluation 31%
JNJ
Intrinsic Value
172.09
USD
Overvaluation 25%
| Company | Last Price | Intrinsic Value | DCF Value | Multiples-Based Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
|
3.22
USD
|
|||||
|
Johnson & Johnson
NYSE:JNJ
|
230.69
USD
|
|||||
No Stocks Selected
Compare the stock's valuation with its competitors.
Valuation Scenario:
Growth Comparison
Growth Over Time
T14, JNJ
T14, JNJ
Revenue
www.alphaspread.com
No Stocks Selected
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Revenue
|
|||||||||||
|
|
Johnson & Johnson
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
No Stocks Selected
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
T14, JNJ
T14, JNJ
Free Cash Flow
www.alphaspread.com
No Stocks Selected
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
|
|||||||||
|
|
Johnson & Johnson
NYSE:JNJ
|
|||||||||
No Stocks Selected
Compare company's free cash flow with its competitors.
Gross Margin
T14
73.3%
JNJ
67.9%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
Operating Margin
T14
18.8%
JNJ
27.9%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
Net Margin
T14
43.3%
JNJ
21.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
FCF Margin
T14
7%
JNJ
20.4%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
ROE
T14
28.5%
JNJ
27.5%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
ROA
T14
19%
JNJ
11.1%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
ROIC
T14
11.5%
JNJ
14.5%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
ROCE
T14
12.2%
JNJ
19.5%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | ||||
|
|
Johnson & Johnson | ||||
Solvency Comparison
Tianjin Pharmaceutical Da Ren Ta...
Equity Waterfall
Assets
Liabilities
Equity
No Stocks Selected
Compare company's equity waterfall with its competitors.
Balance Sheet Comparison
Stocks Performance
Stocks Performance
T14, JNJ
T14, JNJ
Performance By Year
T14, JNJ
T14, JNJ
Loading
No Stocks Selected
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Compare T14 to other stocks
LLY
Eli Lilly and Co
More expensive
vs T14
ROG
Roche Holding AG
Cheaper
vs T14
AZN
AstraZeneca PLC
More expensive
vs T14
MRK
Merck & Co Inc
Cheaper
vs T14
Select Stock to Compare
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Loading...
Unlock Full Access to Alpha Spread
Create Free Account
